Patient Centric Microsampling to Support Paxlovid Clinical Development: Bridging and Implementation
Description
Nirmatrelvir is a potent and selective SARS-CoV-2 main protease inhibitor. Nirmatrelvir co-packaged with ritonavir (as PAXLOVID^(TM) ) received FDA Emergency Use Authorization (EUA) on 22 Dec 2021 as an oral treatment for COVID-19 and subsequent NDA
